Search research articles
Contact Us
Filters
Showing results (391-400 of 423) with videos related to
Page
of 43
Sort By:
International Journal of Cardiology
|
May 1, 2018
Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials
Robert Avram, Guillaume Marquis-Gravel, François Simard, et al.
European Journal of Haematology
|
May 30, 2021
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
Bethany E Monteith, Christopher P Venner, Matthew C Cheung, et al.
American Journal of Hematology
|
March 2, 2021
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial
Christopher P Venner, Richard LeBlanc, Irwindeep Sandhu, et al.
Leukemia & Lymphoma
|
May 16, 2017
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study<sup></sup>
Tanya Skamene, Michael Crump, Kerry J Savage, et al.
Blood
|
June 25, 2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma
Ming Han, Alli Murugesan, Nizar J Bahlis, et al.
Osteoarthritis and Cartilage
|
July 14, 2020
Identification of TGFβ signatures in six murine models mimicking different osteoarthritis clinical phenotypes
M Maumus, D Noël, H K Ea, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 14, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada
Hira S Mian, Alissa Visram, Steven Chun-Min Shih, et al.
British Journal of Haematology
|
May 27, 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP
Douglas A Stewart, John Kuruvilla, David Lee, et al.
Arthritis and Rheumatism
|
March 1, 1996
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus
D Gladman, E Ginzler, C Goldsmith, et al.
Leukemia & Lymphoma
|
October 19, 2016
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group
Matthew D Seftel, John Kuruvilla, Tom Kouroukis, et al.
Page
of 43
Search research articles
Search
Showing results (391-400 of 423) with videos related to
Sort By:
Page
of 43
International Journal of Cardiology
|
May 1, 2018
Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials
Robert Avram, Guillaume Marquis-Gravel, François Simard, et al.
European Journal of Haematology
|
May 30, 2021
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
Bethany E Monteith, Christopher P Venner, Matthew C Cheung, et al.
American Journal of Hematology
|
March 2, 2021
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial
Christopher P Venner, Richard LeBlanc, Irwindeep Sandhu, et al.
Leukemia & Lymphoma
|
May 16, 2017
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study<sup></sup>
Tanya Skamene, Michael Crump, Kerry J Savage, et al.
Blood
|
June 25, 2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma
Ming Han, Alli Murugesan, Nizar J Bahlis, et al.
Osteoarthritis and Cartilage
|
July 14, 2020
Identification of TGFβ signatures in six murine models mimicking different osteoarthritis clinical phenotypes
M Maumus, D Noël, H K Ea, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 14, 2025
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada
Hira S Mian, Alissa Visram, Steven Chun-Min Shih, et al.
British Journal of Haematology
|
May 27, 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP
Douglas A Stewart, John Kuruvilla, David Lee, et al.
Arthritis and Rheumatism
|
March 1, 1996
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus
D Gladman, E Ginzler, C Goldsmith, et al.
Leukemia & Lymphoma
|
October 19, 2016
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group
Matthew D Seftel, John Kuruvilla, Tom Kouroukis, et al.
Page
of 43